TScan Therapeutics (NASDAQ:TCRX) Earns Overweight Rating from Morgan Stanley
Morgan Stanley reaffirmed their overweight rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $10.00 price target on the stock. A number of other equities research analysts also recently commented on the company. Needham & Company LLC cut their price objective […]
Morgan Stanley reaffirmed their overweight rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $10.00 price target on the stock. A number of other equities research analysts also recently commented on the company. Needham & Company LLC cut their price objective […]
-limited-logo-1200x675.png?v=20210413131346&w=240&h=240&zc=2){kind=logo}
